Pre-treatment serum vascular endothelial growth factor is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab


Published Version
doi:10.1186/2051-1426-1-S1-P247

Citable link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:12407008

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Pre-treatment serum vascular endothelial growth factor is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab

Jianda Yuan†, Jun Zhou§, Zhiwan Dong¹, Sapna Tandon¹, Deborah Kuk³, Katherine S Panageas³, Philip Wong¹, Jedd D Wolchok¹,²,⁴, F Stephen Hodi⁵*

From Society for Immunotherapy of Cancer 28th Annual Meeting
National Harbor, MD, USA. 8-10 November 2013

Ipilimumab, an antibody that blocks cytotoxic T lymphocyte antigen 4 (CTLA-4), had shown improved overall survival (OS) for patients with metastatic melanoma. However, predictive biomarkers for clinical benefit have not been well defined. We aimed to evaluate serum vascular endothelial growth factor (VEGF) and its association with clinical benefit and OS for ipilimumab treated advanced melanoma patients. Sera were collected from 176 patients treated with ipilimumab at 3 (n=98) or 10 mg/kg (n=68) from 2005 to 2013. We analyzed serum VEGF at baseline and at the end of induction (week 12) by Meso Scale Discovery kit. The association VEGF with clinical benefit and OS was analyzed using Fisher’s exact test and Kaplan-Meier log-rank test. Pre-treatment VEGF value correlated with clinical benefit for 157 melanoma patients with the availability of clinical response at wk24 (p=0.0111) using

![Figure 1](http://www.immunotherapyofcancer.org/content/1/S1/P247)

**Figure 1** Kaplan Meier curve of overall survival by using 43 pg/ml as the cutoff for baseline VEGF

† Contributed equally
§ Department of Medical Oncology, Center for Immunono-cology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA

Full list of author information is available at the end of the article

© 2013 Yuan et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
43 pg/ml as the cutoff of baseline VEGF value defined by maximally selected log-rank statistics. High level of soluble pre-therapy VEGF (≥ 43 pg/ml) in blood was associated with decreased OS, as compared to low level baseline VEGF (< 43 pg/ml) (Median OS 6.6 vs 12.9 months, p=0.006 for all 176 patients; median OS 7.4 vs 14.3 months, p=0.037 for 3 mg/kg group; median OS 6.2 vs 10.9 months, p=0.048 for 10 mg/kg group, respectively). High level of soluble VEGF at wk12 was correlated with OS in all patients as well (p=0.023). There was no correlation between the change of VEGF and clinical outcome. Serum VEGF may be a predictive biomarker to ipilimumab treatment, and prospective investigation warranted.

Authors’ details
1Ludwig Center for Cancer Immunotherapy, Memorial Sloan-Kettering Cancer Center, New York, NY, USA. 2Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA. 3Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA. 4Weill Cornell Medical College of Cornell University, New York, NY, USA. 5Department of Medical Oncology, Center for Immuno-oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.

Published: 7 November 2013

doi:10.1186/2051-1426-1-S1-P247